Ikeda T
Dept. of Surgery, School of Medicine, Keio University.
Gan To Kagaku Ryoho. 1994 Oct;21 Suppl 3:370-6.
Breast cancer is a solid tumor moderately responsive to chemotherapy and/or endocrine therapy. Based upon meta-analysis covering 233 prospective randomized clinical trials, a consensus about adjuvant chemo and endocrine therapy has been reached according to prognostic factors, including nodal status, tumor size, estrogen receptor and histological grade. The preventive effect of tamoxifen against recurrence has been also proven in Japanese ACETBC (adjuvant chemoendocrine therapy for breast cancer) trials and KEIO BR1 trial. Several other prospective randomized trials have been run in Japan, and the results will be obtained within several years. The features of breast cancer in Japan are low incidence and good prognosis. In these circumstances, the accrual of a vast number of patients and multi-institutional collaboration are essential. The issues under investigation include best chemotherapy dosage and duration, identification of risk factors and the role of preoperative chemotherapy.
乳腺癌是一种对化疗和/或内分泌治疗有中度反应的实体瘤。基于涵盖233项前瞻性随机临床试验的荟萃分析，已根据预后因素（包括淋巴结状态、肿瘤大小、雌激素受体和组织学分级）就辅助化疗和内分泌治疗达成共识。他莫昔芬预防复发的作用也在日本ACETBC（乳腺癌辅助化疗内分泌治疗）试验和庆应义塾BR1试验中得到证实。日本还进行了其他几项前瞻性随机试验，结果将在几年内得出。日本乳腺癌的特点是发病率低和预后良好。在这种情况下，积累大量患者和多机构合作至关重要。正在研究的问题包括最佳化疗剂量和疗程、危险因素的识别以及术前化疗的作用。
